NCT02499224已完成1 期
A Phase I Study to Assess the Safety, Tolerability, and Pharmacokinetics of YYB101, Hepatocyte Growth Factor (HGF)-Neutralizing Humanized Monoclonal Antibody (Mab), in Advanced Solid Tumors Patients Who Are Refractory to Standard Therapy
CellabMED1 个研究点 分布在 1 个国家目标入组 39 人开始时间: 2015年7月13日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 39
- 试验地点
- 1
- 主要终点
- Dose-escalation cohort: DLTs and MTD
研究概览
简要总结
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and maximum tolerated dose (MTD) of YYB101, HGF-neutralizing humanized Mab, in advanced solid tumors patients who are refractory to standard therapy.
详细描述
To evaluate the safety, tolerability, and pharmacokinetics of YYB101, patients who are refractory to standard therapy will be enrolled in this study. In dose-escalation cohort, subjects will be enrolled sequentially into four dose cohorts receiving a single dose of YYB101 (0.3, 1, 3, or 5 mg/kg; 3 or 6 subjects per dose cohort) and will be entered the 4-week treatment-free period to evaluate safety and pharmacokinetics. If no dose-limiting toxicity (DLT) is observed during the 4-week period, YYB101 administration will be resumed at the same dose level every 2 weeks until disease progression or unacceptable toxicity development. After the completion of the dose-escalation cohort, additional subjects will be enrolled into a dose-expansion cohort at the maximum tolerated dose (MTD) or recommended phase II dose (RP2D) for further exploration of safety, tolerability, efficacy and pharmacodynamics.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 19 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female patients aged 19 years or older
- •Patients with pathologically or cytologically confirmed advanced solid tumor which is refractory to standard treatment or for which there is no standard therapy
- •ECOG performance status ≤ 2
- •Life expectancy of ≥ 12 weeks
- •Adequate hematologic, hepatic and renal functions as follows:
- •ANC ≥ 1,500/µL (without G-CSF support within 2 weeks before IP administration)
- •Platelet ≥ 100,000/µL (without transfusion within 2 weeks before IP administration)
- •Hemoglobin ≥ 10.0 g/dL (without transfusion within 4 weeks before IP administration)
- •Serum creatinine ≤ 1.5 mg/dL or eGRF ≥ 60 mL/min/1.73 m2
- •AST and ALT ≤ 2.5 x ULN (AST and ALT ≤ 5 x ULN in the presence of liver metastasis or hepatocarcinoma)
- •Total bilirubin ≤ 1.5 x ULN (with exception of the case associated with Gilbert's syndrome)
- •PT and aPTT ≤ 1.5 x ULN
- •UPC < 1.0 (g/g) (requiring if protein ≥ 1 positive (+) in urinalysis)
- •Patients who voluntarily give written informed consent
排除标准
- •Patients with hematologic malignancies including lymphoma
- •Chemo-, radio-chemo-, biologic-, immuno- or radiotherapy for advanced solid tumor within 4 weeks (or nitrosoureas, mitomycin within 6 weeks or targeted biological antibody within 8 weeks) before IP administration
- •Patients had received high-dose chemotherapy requiring hematopoietic progenitor cell support within 2 years before IP administration
- •Patients with symptomatic central nervous system (CNS) metastasis (patients who are radiologically and neurologically stable condition for ≥ 4 weeks and discontinued corticosteroids at least 4 week before IP administration are able to participate in this trial.)
- •History of deep vein thrombosis or pulmonary embolism within 1 year; Cytomegalovirus (CMV), Epstein-Barr virus (EBV), acute coronary syndrome (including unstable angina or myocardial infarction), or clinically significant cerebrovascular disease (including stroke) within 6 month; Major surgery requiring general anesthesia or respiratory assist within 4 weeks (or video-assisted thoracoscopic surgery or open-and-closed surgery within 2 weeks) before IP administration
- •Concurrent NYHA class III or IV heart failure, uncontrolled hypertension, poorly controlled arrhythmia, other clinically significant cardiovascular abnormalities at investigator's discretion (e.g. LVEF < 50%, clinical significant abnormalities of heart wall, or cardiac muscle damage), known positive result for HIV or other uncontrolled active infection disease
- •Requirement for continuous non-steroidal anti-inflammatory drugs (NSAIDs) or systemic corticosteroids
- •Receiving anticoagulant, history of bleeding diathesis, massive hemoptysis, gastrointestinal hemorrhage, or peptic ulcer disease (< 325 mg aspirin is acceptable)
- •History of severe drug hypersensitivity or hypersensitivity to IP or similar Mab
- •Pregnancy or breast-feeding
- •Women of childbearing potential (WOCBP) or men who are unwilling to use adequate contraception or be abstinent during the trial and for at least 2 months after the end of treatment
- •Patients who received investigational product or investigational device in other clinical trials within 3weeks prior to participation in this trial
- •Patients who cannot participate in this trial at the investigator's discretion
研究组 & 干预措施
YYB101
Experimental
Dose-escalation cohort: YYB101 of each dose level (0.3mg/kg to 5mg/kg), IV infusion on Day 1, Day 29, and followed by every 2 weeks Dose-expansion cohort: YYB101 of MTD (or RP2D), IV infusion every 2 weeks
干预措施: YYB101 (Drug)
结局指标
主要结局
Dose-escalation cohort: DLTs and MTD
时间窗: 28 days
次要结局
- Incidence of AEs that result in discontinuation and dose reduction of YYB101(By 12 months after enrollment of the last subject)
- Clinical laboratory abnormalities that result in discontinuation and dose reduction of YYB101(By 12 months after enrollment of the last subject)
- Area under the plasma concentration versus time curve (AUC) of YYB101(By 4 and 8 weeks after last administration, average 16 weeks)
- Vital sign that result in discontinuation and dose reduction of YYB101(By 12 months after enrollment of the last subject)
- Peak Plasma Concentration (Cmax) of YYB101(By 4 and 8 weeks after last administration, average 16 weeks)
- Anti-YYB101 antibody that result in discontinuation and dose reduction of YYB101(By 12 months after enrollment of the last subject)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of Multiple Ascending Doses of ASP7962 in Healthy SubjectsHealthy VolunteersPharmacokinetics of ASP7962NCT02136316Astellas Pharma Europe B.V.48
招募中
1 期
A Phase I Study of HS-10386 in Participants With Advanced Solid TumorsAdvanced Solid TumorNCT05911464Jiangsu Hansoh Pharmaceutical Co., Ltd.248
终止
1 期
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid TumorsAdvanced Solid TumorsMSI-H/dMMR TumorsCutaneous Squamous Cell CarcinomaUrothelial Carcinoma, HCCEsophageal Squamous Cell CarcinomaSmall-cell Lung CancerCervical CancerMerkel Cell CarcinomaMesotheliomaPD-L1 Amplified Tumor (9p24.1)Cyclin-dependent Kinase 12 Mutated TumorsBasal Cell Carcinoma (Unresectable or Metastatic)Sarcomatoid Renal Cell CarcinomaClear Cell Ovarian or Endometrial CarcinomaAnal CarcinomaSquamous Cell Penile CarcinomaNasopharyngeal CarcinomaDNA Polymerase Epsilon Mutated Tumors (P286R and V411L)NCT04272034Incyte Corporation105
已完成
1 期
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid TumorsAdvanced Solid TumorMSI-H/dMMR TumorsCutaneous Squamous Cell CarcinomaUrothelial CarcinomaEsophageal Squamous Cell CarcinomaCervical CancerHepatoCellular CarcinomaSmall-cell Lung CancerMesotheliomaPD-L1 Amplified Tumor (9p24.1)Merkel Cell CarcinomaNasopharyngeal CarcinomaNCT04242199Incyte Corporation182
已完成
1 期
A Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB086550 in Participants With Advanced Solid TumorsSolid TumorsNCT03762447Incyte Corporation138